{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:36:27Z","timestamp":1790958987164,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T00:00:00Z","timestamp":1614470400000},"content-version":"am","delay-in-days":303,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["CB10647"],"award-info":[{"award-number":["CB10647"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006751","name":"U.S. Army","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006751","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.micpath.2020.104050","type":"journal-article","created":{"date-parts":[[2020,2,9]],"date-time":"2020-02-09T01:11:27Z","timestamp":1581210687000},"page":"104050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Combinations of early generation antibiotics and antimicrobial peptides are effective against a broad spectrum of bacterial biothreat agents"],"prefix":"10.1016","volume":"142","author":[{"given":"Christopher K.","family":"Cote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma I.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Shoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Klimko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha G.","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Welkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4\u20135","key":"10.1016\/j.micpath.2020.104050_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/20477724.2016.1195036","article-title":"Cationic host defense peptides; novel antimicrobial therapeutics against Category A pathogens and emerging infections","volume":"110","author":"Findlay","year":"2016","journal-title":"Pathog. Glob. Health"},{"key":"10.1016\/j.micpath.2020.104050_bib2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fcimb.2016.00194","article-title":"Antimicrobial peptides: an emerging category of therapeutic agents","volume":"6","author":"Mahlapuu","year":"2016","journal-title":"Front. Cell Infect. Microbiol."},{"key":"10.1016\/j.micpath.2020.104050_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.drup.2016.04.002","article-title":"Mechanisms and consequences of bacterial resistance to antimicrobial peptides","volume":"26","author":"Andersson","year":"2016","journal-title":"Drug Resist. Updates"},{"issue":"5","key":"10.1016\/j.micpath.2020.104050_bib4","doi-asserted-by":"crossref","first-page":"547 e1","DOI":"10.1016\/j.cmi.2017.08.029","article-title":"Enhanced efficacy of the engineered antimicrobial peptide WLBU2 via direct airway delivery in a murine model of Pseudomonas aeruginosa pneumonia","volume":"24","author":"Chen","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"issue":"4","key":"10.1016\/j.micpath.2020.104050_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijantimicag.2009.05.012","article-title":"In vitro susceptibility of Burkholderia pseudomallei to antimicrobial peptides","volume":"34","author":"Kanthawong","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"3","key":"10.1016\/j.micpath.2020.104050_bib6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1432-1033.1973.tb02716.x","article-title":"Biosynthesis of melittin, a toxic peptide from bee venom. Amino-acid sequence of the precursor","volume":"33","author":"Kreil","year":"1973","journal-title":"Eur. J. Biochem."},{"issue":"2","key":"10.1016\/j.micpath.2020.104050_bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00203-016-1303-8","article-title":"Characterization of in vitro phenotypes of Burkholderia pseudomallei and Burkholderia mallei strains potentially associated with persistent infection in mice","volume":"199","author":"Bernhards","year":"2017","journal-title":"Arch. Microbiol."},{"key":"10.1016\/j.micpath.2020.104050_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/1471-2180-10-303","article-title":"Effect of colony morphology variation of Burkholderia pseudomallei on intracellular survival and resistance to antimicrobial environments in human macrophages in vitro","volume":"10","author":"Tandhavanant","year":"2010","journal-title":"BMC Microbiol."},{"issue":"2","key":"10.1016\/j.micpath.2020.104050_bib9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.peptides.2012.01.013","article-title":"Design and characterization of novel hybrid antimicrobial peptides based on cecropin A, LL-37 and magainin II","volume":"33","author":"Fox","year":"2012","journal-title":"Peptides"},{"issue":"6","key":"10.1016\/j.micpath.2020.104050_bib10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D","article-title":"Animal antimicrobial peptides: an overview","volume":"47","author":"Andreu","year":"1998","journal-title":"Biopolymers"},{"issue":"14","key":"10.1016\/j.micpath.2020.104050_bib11","doi-asserted-by":"crossref","first-page":"6491","DOI":"10.1016\/S0021-9258(18)68669-7","article-title":"Mastoparan, a peptide toxin from wasp venom, mimics receptors by activating GTP-binding regulatory proteins (G proteins)","volume":"263","author":"Higashijima","year":"1988","journal-title":"J. Biol. Chem."},{"issue":"45","key":"10.1016\/j.micpath.2020.104050_bib12","doi-asserted-by":"crossref","first-page":"28375","DOI":"10.1074\/jbc.271.45.28375","article-title":"Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities","volume":"271","author":"Skerlavaj","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.micpath.2020.104050_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1469-0691.2011.03581.x","article-title":"In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii","volume":"18","author":"Vila-Farres","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"issue":"5","key":"10.1016\/j.micpath.2020.104050_bib14","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1128\/AAC.43.5.1274","article-title":"Improved derivatives of bactenecin, a cyclic dodecameric antimicrobial cationic peptide","volume":"43","author":"Wu","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.micpath.2020.104050_bib15","doi-asserted-by":"crossref","first-page":"e2267","DOI":"10.1371\/journal.pntd.0002267","article-title":"Antimicrobial action of the cyclic peptide bactenecin on Burkholderia pseudomallei correlates with efficient membrane permeabilization","volume":"7","author":"Madhongsa","year":"2013","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"12","key":"10.1016\/j.micpath.2020.104050_bib16","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1021\/acschembio.6b00843","article-title":"Host cell interactions are a significant barrier to the clinical utility of peptide antibiotics","volume":"11","author":"Starr","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"12","key":"10.1016\/j.micpath.2020.104050_bib17","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.bbamem.2017.09.008","article-title":"Antimicrobial peptides are degraded by the cytosolic proteases of human erythrocytes","volume":"1859","author":"Starr","year":"2017","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"2","key":"10.1016\/j.micpath.2020.104050_bib18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1099\/jmm.0.000209","article-title":"Novel engineered cationic antimicrobial peptides display broad-spectrum activity against Francisella tularensis, Yersinia pestis and Burkholderia pseudomallei","volume":"65","author":"Abdelbaqi","year":"2016","journal-title":"J. Med. Microbiol."},{"issue":"8","key":"10.1016\/j.micpath.2020.104050_bib19","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1128\/AAC.49.8.3208-3216.2005","article-title":"Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications","volume":"49","author":"Deslouches","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.micpath.2020.104050_bib20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/AAC.49.1.316-322.2005","article-title":"De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity","volume":"49","author":"Deslouches","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2020.104050_bib21","series-title":"Prokaryotic Antimicrobial Peptides: from Genes to Applications","author":"Drider","year":"2011"},{"issue":"2","key":"10.1016\/j.micpath.2020.104050_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/jac\/42.2.277","article-title":"Activity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model","volume":"42","author":"Goldstein","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.micpath.2020.104050_bib23","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1128\/AAC.02328-12","article-title":"Synergistic effect between colistin and bacteriocins in controlling Gram-negative pathogens and their potential to reduce antibiotic toxicity in mammalian epithelial cells","volume":"57","author":"Naghmouchi","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.micpath.2020.104050_bib24","first-page":"1389","article-title":"Possession, use, and transfer of select agents and toxins; biennial review. Final rule","volume":"7","author":"Centers for Disease Control and Prevention DHHS","year":"2012","journal-title":"Fed. Regist."},{"issue":"Suppl 1","key":"10.1016\/j.micpath.2020.104050_bib25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1469-0691.2007.01852.x","article-title":"Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline","volume":"14","author":"Garau","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"issue":"5","key":"10.1016\/j.micpath.2020.104050_bib26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/14787210.6.5.593","article-title":"Potential of old-generation antibiotics to address current need for new antibiotics","volume":"6","author":"Falagas","year":"2008","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"6","key":"10.1016\/j.micpath.2020.104050_bib27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/jac\/30.6.871","article-title":"Synergy with aztreonam and arbekacin or tobramycin against Pseudomonas aeruginosa isolated from blood","volume":"30","author":"Kobayashi","year":"1992","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.micpath.2020.104050_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10096-009-0833-2","article-title":"Fosfomycin: an old, new friend?","volume":"29","author":"Popovic","year":"2010","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.micpath.2020.104050_bib29","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0924-8579(98)00068-5","article-title":"Fusidic acid adverse drug reactions","volume":"12","author":"Christiansen","year":"1999","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"9","key":"10.1016\/j.micpath.2020.104050_bib30","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1021\/cb300269g","article-title":"A forward chemical screen identifies antibiotic adjuvants in Escherichia coli","volume":"7","author":"Taylor","year":"2012","journal-title":"ACS Chem. Biol."},{"issue":"3","key":"10.1016\/j.micpath.2020.104050_bib31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/07853890109002073","article-title":"Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of gram-negative bacteria","volume":"33","author":"Savage","year":"2001","journal-title":"Ann. Med."},{"issue":"6","key":"10.1016\/j.micpath.2020.104050_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003863","article-title":"Characterization of the Burkholderia mallei tonB mutant and its potential as a backbone strain for vaccine development","volume":"9","author":"Mott","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"issue":"5","key":"10.1016\/j.micpath.2020.104050_bib33","first-page":"1493","article-title":"Distribution and economic importance of anthrax","volume":"26","author":"Sterne","year":"1967","journal-title":"Fed. Proc."},{"issue":"12","key":"10.1016\/j.micpath.2020.104050_bib34","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1128\/IAI.00824-09","article-title":"Role for the Burkholderia pseudomallei capsular polysaccharide encoded by the wcb operon in acute disseminated melioidosis","volume":"77","author":"Warawa","year":"2009","journal-title":"Infect. Immun."},{"key":"10.1016\/j.micpath.2020.104050_bib35","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/archinte.1961.03620050068007","article-title":"Tularemia vaccine study. II. Respiratory challenge","volume":"107","author":"Saslaw","year":"1961","journal-title":"Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.micpath.2020.104050_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/mpat.1997.0154","article-title":"Studies on the role of plasminogen activator in systemic infection by virulent Yersinia pestis strain C092","volume":"23","author":"Welkos","year":"1997","journal-title":"Microb. Pathog."},{"issue":"17\u201318","key":"10.1016\/j.micpath.2020.104050_bib37","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/S0264-410X(02)00119-6","article-title":"Determination of the virulence of the pigmentation-deficient and pigmentation-\/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague","volume":"20","author":"Welkos","year":"2002","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.micpath.2020.104050_bib38","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/jam.12322","article-title":"D-cycloserine or similar physiochemical compounds may be uniquely suited for use in Bacillus anthracis spore decontamination strategies","volume":"115","author":"Omotade","year":"2013","journal-title":"J. Appl. Microbiol."},{"issue":"2","key":"10.1016\/j.micpath.2020.104050_bib39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.mimet.2003.10.019","article-title":"A microtiter fluorometric assay to detect the germination of Bacillus anthracis spores and the germination inhibitory effects of antibodies","volume":"56","author":"Welkos","year":"2004","journal-title":"J. Microbiol. Methods"},{"key":"10.1016\/j.micpath.2020.104050_bib40","series-title":"M7-A5 \u2013 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically","author":"CLSI","year":"2017"},{"issue":"4","key":"10.1016\/j.micpath.2020.104050_bib41","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1128\/AAC.04548-14","article-title":"In vitro antibiotic susceptibilities of Yersinia pestis determined by broth microdilution following CLSI methods","volume":"59","author":"Heine","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.micpath.2020.104050_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00612-17","article-title":"In vitro antibiotic susceptibilities of Francisella tularensis determined by broth microdilution following CLSI methods","volume":"61","author":"Heine","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.micpath.2020.104050_bib43","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.idc.2004.04.012","article-title":"Pharmacodynamics of antimicrobial drugs","volume":"18","author":"Levison","year":"2004","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.micpath.2020.104050_bib44","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically","author":"M7-M5","year":"2017"},{"issue":"11","key":"10.1016\/j.micpath.2020.104050_bib45","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1128\/AAC.00497-10","article-title":"Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii","volume":"54","author":"Sopirala","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.micpath.2020.104050_bib46","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/dki477","article-title":"In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis","volume":"57","author":"Petersen","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.micpath.2020.104050_bib47","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/jac\/11.5.427","article-title":"The fractional inhibitory concentration (FIC) index as a measure of synergy","volume":"11","author":"Hall","year":"1983","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.micpath.2020.104050_bib48","series-title":"Antibiotics in Laboratory Medicine V. Lorian","first-page":"557","article-title":"Antimicrobial combinations","author":"Krogstad","year":"1986"},{"issue":"6","key":"10.1016\/j.micpath.2020.104050_bib49","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0025-7125(05)70294-7","article-title":"Antibiotic synergy and antagonism","volume":"84","author":"Acar","year":"2000","journal-title":"Med. Clin. North Am."},{"issue":"4","key":"10.1016\/j.micpath.2020.104050_bib50","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1128\/AAC.32.4.434","article-title":"Synergistic activity between vancomycin or teicoplanin and gentamicin or tobramycin against pathogenic diphtheroids","volume":"32","author":"Spitzer","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2020.104050_bib51","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fphar.2017.00364","article-title":"Antimicrobial activity and resistance: influencing factors","volume":"8","author":"Li","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.micpath.2020.104050_bib52","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1128\/AAC.11.2.318","article-title":"Tetracycline inhibits propagation of deoxyribonucleic acid replication and alters membrane properties","volume":"11","author":"Pato","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.micpath.2020.104050_bib53","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrmicro2333","article-title":"How antibiotics kill bacteria: from targets to networks","volume":"8","author":"Kohanski","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.micpath.2020.104050_bib54","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fcimb.2019.00128","article-title":"Application of antimicrobial peptides of the innate immune system in combination with conventional antibiotics-A novel way to combat antibiotic resistance?","volume":"9","author":"Zharkova","year":"2019","journal-title":"Front. Cell Infect. Microbiol."},{"issue":"2","key":"10.1016\/j.micpath.2020.104050_bib55","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4065\/mcp.2010.0639","article-title":"General principles of antimicrobial therapy","volume":"86","author":"Leekha","year":"2011","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.micpath.2020.104050_bib56","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"issue":"6","key":"10.1016\/j.micpath.2020.104050_bib57","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s15010-011-0161-1","article-title":"Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy","volume":"39","author":"Guner","year":"2011","journal-title":"Infection"},{"issue":"5","key":"10.1016\/j.micpath.2020.104050_bib58","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1128\/JCM.02466-08","article-title":"Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection","volume":"47","author":"Lee","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.micpath.2020.104050_bib59","article-title":"Antimicrobial peptides: a potential therapeutic option for surgical site infections","volume":"2","author":"Deslouches","year":"2017","journal-title":"Clin. Surg."},{"issue":"1","key":"10.1016\/j.micpath.2020.104050_bib60","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.febslet.2006.12.003","article-title":"Interaction mode of a symmetric Trp-rich undeca peptide PST11-RK with lipid bilayers","volume":"581","author":"Yang","year":"2007","journal-title":"FEBS Lett."},{"issue":"12","key":"10.1016\/j.micpath.2020.104050_bib61","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.chembiol.2014.10.009","article-title":"The host antimicrobial peptide Bac71-35 binds to bacterial ribosomal proteins and inhibits protein synthesis","volume":"21","author":"Mardirossian","year":"2014","journal-title":"Chem. Biol."},{"issue":"9","key":"10.1016\/j.micpath.2020.104050_bib62","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tibtech.2011.05.001","article-title":"The expanding scope of antimicrobial peptide structures and their modes of action","volume":"29","author":"Nguyen","year":"2011","journal-title":"Trends Biotechnol."},{"issue":"8","key":"10.1016\/j.micpath.2020.104050_bib63","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/jac\/dkw143","article-title":"Engineered cationic antimicrobial peptide (eCAP) prevents Pseudomonas aeruginosa biofilm growth on airway epithelial cells","volume":"71","author":"Lashua","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"34","key":"10.1016\/j.micpath.2020.104050_bib64","doi-asserted-by":"crossref","first-page":"8841","DOI":"10.1016\/j.biomaterials.2012.08.026","article-title":"Cationic amphiphilic alpha-helical peptides for the treatment of carbapenem-resistant Acinetobacter baumannii infection","volume":"33","author":"Huang","year":"2012","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.micpath.2020.104050_bib65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1128\/AAC.00796-07","article-title":"Comparative analysis of the bactericidal activities of amphibian peptide analogues against multidrug-resistant nosocomial bacterial strains","volume":"52","author":"Mangoni","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.micpath.2020.104050_bib66","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrmicro1441","article-title":"The co-evolution of host cationic antimicrobial peptides and microbial resistance","volume":"4","author":"Peschel","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"issue":"13","key":"10.1016\/j.micpath.2020.104050_bib67","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1073\/pnas.0500508102","article-title":"Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences","volume":"102","author":"Kim","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.micpath.2020.104050_bib68","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1128\/AAC.00267-11","article-title":"Humanized theta-defensins (retrocyclins) enhance macrophage performance and protect mice from experimental anthrax infections","volume":"55","author":"Welkos","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"14","key":"10.1016\/j.micpath.2020.104050_bib69","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1021\/jm0703542","article-title":"Albumin binding of short cationic antimicrobial micropeptides and its influence on the in vitro bactericidal effect","volume":"50","author":"Svenson","year":"2007","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.micpath.2020.104050_bib70","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ijantimicag.2010.06.001","article-title":"Chicken cathelicidin-2-derived peptides with enhanced immunomodulatory and antibacterial activities against biological warfare agents","volume":"36","author":"Molhoek","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"3","key":"10.1016\/j.micpath.2020.104050_bib71","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.bbamem.2015.11.003","article-title":"The human cathelicidin LL-37--A pore-forming antibacterial peptide and host-cell modulator","volume":"1858","author":"Xhindoli","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.micpath.2020.104050_bib72","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1600-065X.2011.01082.x","article-title":"alpha-Defensins in human innate immunity","volume":"245","author":"Lehrer","year":"2012","journal-title":"Immunol. Rev."},{"issue":"Suppl 4","key":"10.1016\/j.micpath.2020.104050_bib73","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1016\/S0924-8579(09)70005-6","article-title":"A review of tigecycline--the first glycylcycline","volume":"32","author":"Peterson","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"2","key":"10.1016\/j.micpath.2020.104050_bib74","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/AAC.02465-15","article-title":"Potential of tetracycline resistance proteins to evolve tigecycline resistance","volume":"60","author":"Linkevicius","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.micpath.2020.104050_bib75","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/jac\/dkr242","article-title":"Efficacy and safety of tigecycline: a systematic review and meta-analysis","volume":"66","author":"Yahav","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"issue":"9","key":"10.1016\/j.micpath.2020.104050_bib76","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","article-title":"Safety of doxycycline and minocycline: a systematic review","volume":"27","author":"Smith","year":"2005","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.micpath.2020.104050_bib77","volume":"63","author":"Flamm","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.micpath.2020.104050_bib78","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bph.12139","article-title":"Minocycline: far beyond an antibiotic","volume":"169","author":"Garrido-Mesa","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.micpath.2020.104050_bib79","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1021\/id500013t","article-title":"A new-class Antibacterial-almost. Lessons in drug discovery and development: a critical analysis of more than 50 Years of effort toward ATPase inhibitors of DNA gyrase and topoisomerase IV","volume":"1","author":"Bisacchi","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.micpath.2020.104050_bib80","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.biopha.2018.04.021","article-title":"DNA gyrase inhibitors: progress and synthesis of potent compounds as antibacterial agents","volume":"103","author":"Khan","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.micpath.2020.104050_bib81","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jac\/dkh471","article-title":"Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents","volume":"54","author":"Thibault","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/j.micpath.2020.104050_bib82","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/toxins4070536","article-title":"Bacillus anthracis factors for phagosomal escape","volume":"4","author":"Tonello","year":"2012","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.micpath.2020.104050_bib83","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fcimb.2013.00106","article-title":"Yersinia pestis: mechanisms of entry into and resistance to the host cell","volume":"3","author":"Ke","year":"2013","journal-title":"Front. Cell Infect. Microbiol."},{"issue":"4","key":"10.1016\/j.micpath.2020.104050_bib84","doi-asserted-by":"crossref","first-page":"a010314","DOI":"10.1101\/cshperspect.a010314","article-title":"Mechanisms of Francisella tularensis intracellular pathogenesis","volume":"3","author":"Celli","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"10","key":"10.1016\/j.micpath.2020.104050_bib85","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00468-17","article-title":"Entry, intracellular survival, and multinucleated-giant-cell-forming activity of Burkholderia pseudomallei in human primary phagocytic and nonphagocytic cells","volume":"85","author":"Whiteley","year":"2017","journal-title":"Infect. Immun."},{"issue":"Pt 5","key":"10.1016\/j.micpath.2020.104050_bib86","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1099\/jmm.0.007724-0","article-title":"Burkholderia mallei cellular interactions in a respiratory cell model","volume":"58","author":"Whitlock","year":"2009","journal-title":"J. Med. Microbiol."},{"issue":"8","key":"10.1016\/j.micpath.2020.104050_bib87","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbamem.2008.09.013","article-title":"Control of cell selectivity of antimicrobial peptides","volume":"1788","author":"Matsuzaki","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.micpath.2020.104050_bib88","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.biochi.2010.02.023","article-title":"Structural determinants of host defense peptides for antimicrobial activity and target cell selectivity","volume":"92","author":"Takahashi","year":"2010","journal-title":"Biochimie"},{"key":"10.1016\/j.micpath.2020.104050_bib89","unstructured":"Safety Data Sheet-Dimethyl sulfoxide (DMSO). Sigma Aldrich, Version 6.4, Revised 01-15-20."},{"issue":"12","key":"10.1016\/j.micpath.2020.104050_bib90","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.1128\/AAC.01357-16","article-title":"Potential use of dimethly sulfoxide in treatment of infections caused by Pseudomonas aeruginosa","volume":"60","author":"Guo","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.micpath.2020.104050_bib91","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0090-4295(78)90118-8","article-title":"Dimethyl sulfoxide in treatment of inflammatory genitourinary disorders","volume":"11","author":"Shirley","year":"1978","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.micpath.2020.104050_bib92","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/00498254.2013.845706","article-title":"Solvent-based formulations for intravenous mouse pharmacokinetic studies: tolerability and recommended solvent dose limits","volume":"44","author":"Thackaberry","year":"2014","journal-title":"Xenobiotica"},{"key":"10.1016\/j.micpath.2020.104050_bib93","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0041-008X(69)90027-1","article-title":"The toxicity of four concentrations of DMSO","volume":"15","author":"Worthley","year":"1969","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.micpath.2020.104050_bib94","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/dkm253","article-title":"De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia","volume":"60","author":"Deslouches","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.micpath.2020.104050_bib95","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1128\/AAC.03937-14","article-title":"Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens","volume":"59","author":"Deslouches","year":"2015","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401019321084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401019321084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:51:25Z","timestamp":1777575085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401019321084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":95,"alternative-id":["S0882401019321084"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2020.104050","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combinations of early generation antibiotics and antimicrobial peptides are effective against a broad spectrum of bacterial biothreat agents","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2020.104050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104050"}}